Modeling lymphocyte subset dynamics after ublituximab therapy in patients with multiple sclerosis: an Italian prospective study
In our cohort, ublituximab induced rapid, durable CD19<sup>+</sup> naive B-cell depletion with only transient, reversible effects on other lymphocyte subsets and preserved immunoglobulin levels. This signature extends to older and high BMI patients, supporting ublituximab as a versatile therapeutic option across heterogeneous MS populations.
Authors
- Cristina Rutigliano
- Carlo Avolio (ORCID: https://orcid.org/0000-0002-0987-1967)
- Aurora Zanghì (ORCID: https://orcid.org/0000-0002-9566-3135)
- Gaetano Corso (ORCID: https://orcid.org/0000-0003-4720-1320)
- Massimo Papale (ORCID: https://orcid.org/0000-0002-8278-5045)
- Emanuele D’Amico (ORCID: https://orcid.org/0000-0001-7494-9057)
- Paola Sofia Di Filippo
- Maria Claudia Moretti
Institutions
- University of Foggia (IT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-21
- DOI
- https://doi.org/10.3389/fimmu.2025.1688090
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00